291 related articles for article (PubMed ID: 36516540)
1. Association between serum levels of 12 different cytokines and short-term efficacy of anti-PD-1 monoclonal antibody combined with chemotherapy in advanced gastric cancer.
Qi Q; Peng Y; Zhu M; Zhang Y; Bao Y; Zhang X; Zhang J; Liu Y
Int Immunopharmacol; 2023 Jan; 114():109553. PubMed ID: 36516540
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of 12 different cytokines correlate to PD-1 inhibitor combined chemotherapy responses in advanced non-small-cell lung cancer patient.
Peng Y; Qi Q; Zhu M; Zhang Y; Bao Y; Liu Y
Int Immunopharmacol; 2023 Nov; 124(Pt A):110888. PubMed ID: 37690239
[TBL] [Abstract][Full Text] [Related]
3. Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer.
Hou Y; Li X; Yang Y; Shi H; Wang S; Gao M
Front Immunol; 2023; 14():1274431. PubMed ID: 38022654
[TBL] [Abstract][Full Text] [Related]
4. Serum IL-5 and IFN-
Zhao Q; Bi Y; Sun H; Xiao M
Dis Markers; 2021; 2021():5526885. PubMed ID: 34239620
[TBL] [Abstract][Full Text] [Related]
5. An On-Treatment Decreased Trend of Serum IL-6 and IL-8 as Predictive Markers Quickly Reflects Short-Term Efficacy of PD-1 Blockade Immunochemotherapy in Patients with Advanced Gastric Cancer.
Liu J; Mao Y; Mao C; Wang D; Dong L; Zhu W
J Immunol Res; 2024; 2024():3604935. PubMed ID: 38774604
[TBL] [Abstract][Full Text] [Related]
6. Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy.
Shi Y; Liu X; Du J; Zhang D; Liu J; Chen M; Zhao J; Zhong W; Xu Y; Wang M
Thorac Cancer; 2022 Jan; 13(2):219-227. PubMed ID: 34825500
[TBL] [Abstract][Full Text] [Related]
7. PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer.
Chen H; Jiang T; Lin F; Guan H; Zheng J; Liu Q; Du B; Huang Y; Lin X
Int Immunopharmacol; 2021 Oct; 99():107929. PubMed ID: 34343940
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study.
Yuan M; Zhu Z; Mao W; Wang H; Qian H; Wu J; Guo X; Xu Q
Front Oncol; 2021; 11():683502. PubMed ID: 34692475
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors.
Schindler H; Lusky F; Daniello L; Elshiaty M; Gaissmaier L; Benesova K; Souto-Carneiro M; Angeles AK; Janke F; Eichhorn F; Kazdal D; Schneider M; Liersch S; Klemm S; Schnitzler P; Stenzinger A; Sültmann H; Thomas M; Christopoulos P
Front Oncol; 2022; 12():1010660. PubMed ID: 36387148
[TBL] [Abstract][Full Text] [Related]
10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
11. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
Front Immunol; 2022; 13():987568. PubMed ID: 36159840
[TBL] [Abstract][Full Text] [Related]
12. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study.
Sánchez-Zauco N; Torres J; Gómez A; Camorlinga-Ponce M; Muñoz-Pérez L; Herrera-Goepfert R; Medrano-Guzmán R; Giono-Cerezo S; Maldonado-Bernal C
BMC Cancer; 2017 May; 17(1):384. PubMed ID: 28558708
[TBL] [Abstract][Full Text] [Related]
15. Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients.
Wang Y; Chen H; Zhang T; Yang X; Zhong J; Wang Y; Chi Y; Wu M; An T; Li J; Zhao X; Dong Z; Wang Z; Zhao J; Zhuo M; Huang J
Ann Transl Med; 2021 Jan; 9(1):33. PubMed ID: 33553326
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
17. [Clinical analysis of immunotherapy rechallenge in advanced gastric cancer].
Zhang XX; Yang XF; Li S; Wu C; Hou XF
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):605-612. PubMed ID: 37462017
[No Abstract] [Full Text] [Related]
18. Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma.
Shibata Y; Kishida T; Kouro T; Wei F; Igarashi Y; Himuro H; Noguchi T; Koizumi M; Suzuki T; Osaka K; Saigusa Y; Sasada T
Front Pharmacol; 2023; 14():1269935. PubMed ID: 38026978
[No Abstract] [Full Text] [Related]
19. Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer.
Wu C; Qiu Y; Zhang R; Li X; Liang H; Wang M; Li F; Zhu M; Ye G; Liu H; Li G; Zhao L
J Transl Med; 2022 Sep; 20(1):386. PubMed ID: 36058929
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer.
Liang H; Yan X; Li Z; Chen X; Qiu Y; Li F; Wang M; Huang Z; Huang K; Xie Q; Zhang H; Zhong R; Zhao Z; Zou Y; Yu J; Hu Y; Liu H; Li G; Zhao L
Int J Surg; 2023 Dec; 109(12):4162-4172. PubMed ID: 37720943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
